Publications
Articles and Abstracts
Injectable luteinizing hormone–releasing hormone agonists (e.g., leuprolide) are the standard agents for achieving androgen deprivation for prostate cancer despite the initial testosterone surge and delay in therapeutic effect. The efficacy and safety of relugolix, an oral gonadotropin-releasing hormone antagonist, as compared with those of leuprolide are not known.

External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for patients with intermediate- and high-risk prostate cancer (PCa).

Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Bertrand Tombal, MD, PhD,
At the ESMO 2021 annual meeting Dr. Bertrand Tombal presented a subgroup analysis of the phase 3 HERO study assessing the efficacy and safety of relugolix versus leuprolide among men with advanced prostate cancer.
Presented by Bertrand Tombal, MD, PhD
At the ESMO 2021 annual meeting, Dr. Bertrand Tombal presented a subgroup analysis of the phase 3 HERO study assessing geographical efficacy and safety of relugolix versus leuprolide among men with advanced prostate cancer.
Presented by Michael Cookson, MD, MMHC
Androgen deprivation therapy (ADT) is a cornerstone of prostate cancer treatment and is usually achieved with luteinizing hormone-releasing hormone (LHRH) agonists or gonadotropin-releasing hormone (GnRH) antagonists.
Presented by Daniel J. George, MD
Dr. Daniel George and colleagues presented a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of the oral GnRH receptor antagonist relugolix versus leuprolide in men with advanced prostate cancer. 
Presented by Neal Shore, MD, FACS
(UroToday.com) Neal Shore, MD, FACS, presented the HERO Phase III trial assessing the role of relugolix, an oral GnRH receptor antagonist, compared to leuprolide acetate for advanced prostate cancer. Prostate cancer is the most common cancer diagnosis and the second most common cause of cancer death in US men, as shown in Figure 1. It is also known that cardiovascular mortality is the leading cause of death in patients with prostate cancer.
Presented by Elahe A. Mostaghel, MD, PhD
(UroToday.com) As part of the 2020 ASCO Virtual Annual Meeting Prostate Cancer Oral Abstract Session, Dr. Elahe Mostaghel from Fred Hutchinson Cancer Research Center in Seattle, Washington, provided a discussant presentation assessing the role of androgen deprivation therapy (ADT) for advanced prostate cancer.
Presented by Neal Shore, MD, FACS
(UroToday.com) Androgen deprivation is the backbone of treatment for men with metastatic prostate cancer. The current standard of care is leuprolide or degarelix, both given as subcutaneous injections. While degarelix is only available as a one-month formulation, leuprolide is available in 1, 3, or 6-month depo injections, which offers significant convenience for patients.
Presented by Neal D. Shore, MD, FACS
LHRH agonists are the mainstay for medical castration in advanced prostate cancer, however, they cause an initial testosterone surge with a delayed onset of castration and require depot injection. Although prostate cancer is the most common cancer diagnosis and the second most common cause of cancer death in US men, cardiovascular mortality is the leading cause of death in patients with prostate cancer.  Relugolix is the first oral GnRH receptor antagonist, which was previously shown to rapidly suppress testosterone levels.